Analysis of Expression of Specific Markers in Hepatocellular Carcinoma

Completed

• Conditions: Hepatocellular Carcinoma

• Registration Number: NCT00858000
• Lead Sponsor: GlaxoSmithKline

Brief Summary

Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these. As a first step in the development of novel therapies, expression analysis of specific markers, including tumor antigens will be carried out. This will be done retrospectively using available hepatocellular carcinoma tissue samples.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-03-05
• Study First Submitted QC: 2009-03-05
• Study First Posted: 2009-03-09
• Study Start: 2009-07
• Status Verified: 2009-12
• Primary Completion: 2009-12
• Study Completion: 2009-12
• Last Update Submitted: 2009-12-23
• Last Update Posted: 2009-12-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• The patient had pathologically proven hepatocellular carcinoma
• All the data required are available from patient's records
• A sufficient amount of RNA is available for all three tissue samples

Exclusion Criteria

N/A

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of hepatocellular carcinoma cancer patients whose tumor tissue -expresses any one or more of specific target antigens -overexpresses c-MET -expresses a pre-defied gene-expression signature	At the time of analysis.
This study will also analyze whether this gene-expression signature is present in matched cirrhotic tissue and the interface tissue with the tumor.	At the time of analysis.

Trial Locations

Locations (1)

GSK Investigational Site; 🇮🇹 Firenze, Toscana, Italy